Grants and Contributions:
Title:
Development and Evaluation of Aptamers Against the Hepatitic C Virus Core Protein
Agreement Number:
910621
Agreement Value:
$50,000.00
Agreement Date:
Jul 1, 2018 - Mar 15, 2019
Description:
Aptamers are DNA or RNA constructs designed to specifically bind to a desired target. This project is designed to develop aptamers that target the HCV Core protein and perform initial analyses to determine if aptamers can be used in future rapid diagnostic test kits.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Richmond, British Columbia, CA V6V 2X7
Reference Number:
172-2018-2019-Q2-910621
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
869859116
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 74 days.
Amendment Date
Dec 6, 2018
Recipient's Legal Name:
BioLytical Laboratories Inc.
Federal Riding Name:
Steveston--Richmond East
Federal Riding Number:
59031
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
334512
Amendments: